Equities research analysts expect that Acceleron Pharma Inc. (NASDAQ:XLRN) will report $3.37 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Acceleron Pharma’s earnings, with estimates ranging from $2.76 million to $4.40 million. Acceleron Pharma also posted sales of $3.37 million in the same quarter last year. The business is scheduled to report its next earnings results on Wednesday, March 7th.

On average, analysts expect that Acceleron Pharma will report full year sales of $3.37 million for the current year, with estimates ranging from $12.54 million to $14.50 million. For the next financial year, analysts expect that the business will post sales of $27.98 million per share, with estimates ranging from $13.20 million to $37.00 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Acceleron Pharma.

Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The company had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $3.52 million. During the same period last year, the firm earned ($0.55) EPS. The firm’s revenue for the quarter was up .0% on a year-over-year basis.

Several analysts have recently commented on XLRN shares. HC Wainwright started coverage on Acceleron Pharma in a report on Thursday, October 12th. They issued a “buy” rating and a $57.00 price target for the company. UBS reissued a “buy” rating and issued a $50.00 price target (up from $36.00) on shares of Acceleron Pharma in a report on Tuesday, September 12th. Credit Suisse Group set a $35.00 price target on Acceleron Pharma and gave the company a “buy” rating in a report on Saturday, August 5th. Royal Bank Of Canada reissued a “hold” rating on shares of Acceleron Pharma in a report on Thursday, November 2nd. Finally, Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a report on Tuesday, September 5th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $44.56.

In related news, CFO Kevin F. Mclaughlin sold 16,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $38.41, for a total value of $614,560.00. Following the completion of the transaction, the chief financial officer now directly owns 50,810 shares of the company’s stock, valued at approximately $1,951,612.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP John D. Quisel sold 5,113 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $38.42, for a total value of $196,441.46. Following the completion of the transaction, the senior vice president now directly owns 57,918 shares of the company’s stock, valued at $2,225,209.56. The disclosure for this sale can be found here. Insiders sold a total of 53,513 shares of company stock valued at $2,055,485 over the last ninety days. 3.90% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XLRN. Perceptive Advisors LLC increased its stake in Acceleron Pharma by 127.2% in the 3rd quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock valued at $60,319,000 after purchasing an additional 905,000 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in Acceleron Pharma by 46.6% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock valued at $51,127,000 after purchasing an additional 534,440 shares in the last quarter. Sectoral Asset Management Inc increased its stake in Acceleron Pharma by 378.2% in the 2nd quarter. Sectoral Asset Management Inc now owns 604,499 shares of the biopharmaceutical company’s stock valued at $18,371,000 after purchasing an additional 478,099 shares in the last quarter. BlackRock Inc. increased its stake in Acceleron Pharma by 9.0% in the 2nd quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock valued at $121,719,000 after purchasing an additional 330,635 shares in the last quarter. Finally, AXA purchased a new position in Acceleron Pharma in the 2nd quarter valued at approximately $9,833,000. 85.73% of the stock is owned by hedge funds and other institutional investors.

Shares of Acceleron Pharma (XLRN) opened at $35.54 on Friday. Acceleron Pharma has a 1-year low of $23.07 and a 1-year high of $40.35.

TRADEMARK VIOLATION WARNING: “$3.37 Million in Sales Expected for Acceleron Pharma Inc. (XLRN) This Quarter” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/03/3-37-million-in-sales-expected-for-acceleron-pharma-inc-xlrn-this-quarter-2.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Get a free copy of the Zacks research report on Acceleron Pharma (XLRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.